# Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT03936153** · PHASE2 · RECRUITING · sponsor: **Xynomic Pharmaceuticals, Inc.** · enrollment: 170 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** abexinostat

## Key facts

- **NCT ID:** NCT03936153
- **Lead sponsor:** Xynomic Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-01-20
- **Primary completion:** 2026-07-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03936153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03936153, "Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT03936153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*